Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. (Q33960788)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Jonas Busch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Christoph Seidel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Steffen Weikert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Carsten Kempkensteffen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Lisa Weinkauf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Stefan Hinz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Ahmed Magheli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kurt Miller

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Viktor Grünwald

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

14 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

7 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Sunitinib rechallenge in metastatic renal cell carcinoma patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Sequential use of targeted agents in the treatment of renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Resistance to targeted therapy in renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Targeting mTOR in renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Modes of resistance to anti-angiogenic therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3154177

Effect of p53 status on tumor response to antiangiogenic therapy.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-295

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-295

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-295

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-295

21 January 2018

Identifiers

DOI

10.1186/1471-2407-11-295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21756335%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

21756335

1 reference